ZINZINO AB (PUBL): PRELIMINARY SALES REPORT APRIL 2019

Strong sales growth during April; Zinzino based revenue increased 36% and the total group revenue with a total of 29% compared with the previous year. 

The revenue for Zinzino's sales markets increased by 36% to SEK 53.4 (39.4) million due to strong growth foremost in Central Europe. Faun Pharma's external sales decreased by 8% and amounted to SEK 6.1 (6.6) million. Overall, the Group increased revenues by 29 % to SEK 59.5 (46.0) million compared with the previous year.

Accumulated income January - April increased by 24% to SEK 227.7 (183.7) million compared with the previous year.

Revenues distributed as follows:

Regions,Msek Apr-19 Apr-18 Change YTD 2019 YTD 2018 Change
Baltic Markets 4.4 3.7 20% 18.0 14.1 27%
Nordic Markets 29.1 29.0 1% 125.7 121.9 3%
Europe Other Markets 17.4 5.3 229% 60.4 19.6 209%
North America 2.1 1.5 46% 7.3 6.3 16%
Australia 0.3 0.0 0.3 0,0
Zinzino 53.4 39.4 36% 211.7 161.9 31%
Faun Pharma 6.1 6.6 -8% 16.0 21.8 -26%
Zinzino Group 59.5 46.0 29% 227.7 183.7 24%

The sales figures are prepared according to IFRS. Adjustment for IFRS 15, income from customers has affected comparative figures.

For more information please contact:
Dag Bergheim Pettersen, CEO Zinzino, tel. +47 (0) 932 25 700
Zinzino.com

Pictures for free publication:
Marcus Tollbom, tel. +46 (0) 70-190 03 12

Certified Adviser:
Erik Penser Bank Aktiebolag: +46 (0)8 463 83 00 Email: certifiedadviser@penser.se 

Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations
governing market abuse. The information was provided by the above contact person for publication at 10:00 the 14th of May, 2019.

Tags:

About Us

Zinzino AB (publ.) is a direct sales company which operates through the EU, North America and Australia. Zinzino markets and sells products in two product lines: Zinzino Health, with a focus on long-term health, and Zinzino Coffee, consisting of espresso machines, coffee and tea. Zinzino owns Norwegian BioActive Foods AS and the research and production unit Faun Pharma AS. Zinzino has over 120 employees. The company has its registered office in Gothenburg, and offices in Helsinki, Riga, Oslo, Florida and Brisbane. Zinzino is a public limited company and its shares are listed on Nasdaq First North.

Subscribe

Documents & Links